Molecular and immune biomarkers in acute respiratory distress syndrome a perspective from members of the pulmonary pathology society

Archives of Pathology and Laboratory Medicine

Volumn 141, Issue 12, 2017, Pages 1719-1727

  Capelozzi, Vera Luiza ^a   Allen, Timothy Craig ^b   Beasley, Mary Beth ^c   Cagle, Philip T ^d   Guinee, Don ^e   Hariri, Lida P ^f   Husain, Aliya N ^g   Jain, Deepali ^h   Lantuejoul, Sylvie ^i,j   Larsen, Brandon T ^k   Miller, Ross ^d   Mino Kenudson, Mari ^f   Mehrad, Mitra ^l   Raparia, Kirtee ^m   Roden, Anja ⁿ   Schneider, Frank ^o   Sholl, Lynette M ^p   Smith, Maxwell Lawrence ^k  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ CENTRE LÉON BÉRARD   (France)

^j UNIV GRENOBLE ALPES   (France)

^k MAYO CLINIC   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ MAYO CLINIC ROCHESTER   (United States)

^o UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^p BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; IMMUNOLOGY; MEDICAL SOCIETY; METABOLISM; PATHOLOGY; PROGNOSIS; PULMONOLOGY; UNITED STATES;

ANIMALS; BIOMARKERS; ENDOTHELIAL CELLS; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; INFLAMMATION MEDIATORS; PATHOLOGY, CLINICAL; PROGNOSIS; PULMONARY MEDICINE; RESPIRATORY DISTRESS SYNDROME, ADULT; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85037058535     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2017-0115-SA     Document Type: Article

References (72)

1. Cross L J M, Matthay MA. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury. Crit Care Clin. 2011;27(2):355-377.
2. Ware LB, Matthay MA. The acute respiratory distress syndrome [published comment appears in N Engl J Med. 2000;343(9): 660-661]. N Engl J Med. 2000;342(18):1334-1349.
3. González-López A, Albaiceta GM. Repair after acute lung injury: molecular mechanisms and therapeutic opportunities. Crit Care. 2012;16(2):209-216.
4. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526-2533.
5. Frank AJ, Thompson BT. Pharmacological treatments for acute respiratory distress syndrome. Curr Opin Crit Care. 2010;16(1):62-68.
6. Griffiths MJ, McAuley DF. RAGE: a biomarker for acute lung injury [comment]. Thorax. 2008;63(12):1034-1036.
7. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and metaanalysis. Crit Care Med. 2014;42(3):691-700.
8. Bhargava M, Wendt CH. Biomarkers in acute lung injury. Transl Res. 2012;159(4):205-217.
9. Barnett N, Ware LB. Biomarkers in acute lung injury: marking forward progress. Crit Care Clin. 2011;27(3):661-683.
10. Proudfoot AG, Hind M, Griffiths MJ. Biomarkers of acute lung injury: worth their salt? BMC Med. 2011;9:132.
11. Beloncle F, Lorente JA, Esteban A, Brochard L. Update in acute lung injury and mechanical ventilation 2013. Am J Respir Crit Care Med. 2014;189(10):1187-1193.
12. Butt Y, Kurdowska A, Allen TC. Acute lung injury: a clinical and molecular review. Arch Pathol Lab Med. 2016;140(4):345-350.
13. Walter JM, Wilson J, Ware LB. Biomarkers in acute respiratory distress syndrome: from pathobiology to improving patient care. Expert Rev Respir Med. 2014;8(5):573-586.
14. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620.
15. Blondonnet R, Constantin JM, Sapin V, Jabaudon M. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers. 2016;2016:350-373.
16. Bhargava M1, Wendt CH. Biomarkers in acute lung injury. Transl Res. 2012;159(4):205-217.
17. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage-the role of oxygen, shock, and related factors: a review. Am J Pathol. 1976;85(1):209-228.
18. Beasley MB. The pathologist's approach to acute lung injury. Arch Pathol Lab Med. 2010;134(5):719-727.
19. Allen TC, Kurdowska A. Interleukin 8 and Acute Lung Injury. Arch Pathol Lab Med. 2014;138(2):266-269.
20. Menezes, LS, Bozza PT, Faria Neto H C C, et al. Pulmonary and extrapulmonary acute lung injury: inflammatory and ultrastructural analyses. J Appl Physiol. 2005;98(5):1777-1783.
21. Leite-Junior H P L, Garcia C S N B, Souza-Fernandes AB, et al. Methylprednisolone improves lung mechanics and reduces the inflammatory response in pulmonary but not in extrapulmonary mild acute lung injury in mice. Crit Care Med. 2008;36(9):2621.
22. Araújo IM, Abreu SC, Maron-Gutierrez T, et al. Bone marrow-derived mononuclear cell therapy in experimental pulmonary and extrapulmonary acute lung injury. Crit Care Med. 2010;38(8):1733-1741.
23. Bauer TT, Montón C, Torres A, et al. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 2000;55(1):46-52.
24. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1b and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107(4):1062-1073.
25. Donahoe M, Valentine VG, Chien N, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis [published correction appears in PLoS One. 2015;10(7): e0133684]. PLoS One. 2015;10(6):e0127771.
26. Dolinay T, Kim YS, Howrylak J, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012;185(11):1225-1234.
27. Makabe H, Kojika M, Takahashi G, et al. Interleukin-18 levels reflect the long-term prognosis of acute lung injury and acute respiratory distress syndrome. J Anesth. 2012;26(5):658-663.
28. Parsons PE, Matthay MA, Ware LB, Eisner MD; National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(3):L426-L431.
29. Calfee CS, Eisner MD, Ware LB, et al; National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med. 2007;35(10):2243-2250.
30. Lo CJ, Fu M, Cryer HG. Interleukin 10 inhibits alveolar macrophage production of inflammatory mediators involved in adult respiratory distress syndrome. J Surg Res. 1998;79(2):179-184.
31. Jabaudon M, Blondonnet R, Roszyk L, et al. Soluble forms and ligands of the receptor for advanced glycation end-products in patients with acute respiratory distress syndrome: an observational prospective study. PLoS One. 2015;10(8):e0135857.
32. Villar J, Pérez-Méndez L, Espinosa E, et al; GRECIA and GEN-SEP Groups. Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One. 2009;4(8):e6818.
33. Sittipunt C, Steinberg KP, Ruzinski JT, et al. Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(2):503-510.
34. Bajwa EK, Khan UA, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest. 2009;136(2):471-480.
35. Hoeboer SH, Oudemans-van Straaten HM, Groeneveld AB. Albumin rather than C-reactive protein may be valuable in predicting and monitoring the severity and course of acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new onset fever. BMC Pulm Med. 2015;15:22.
36. Silva PL, Cruz FF, Fujisaki LC, et al. Hypervolemia induces and potentiates lung damage after recruitment maneuver in a model of sepsis-induced acute lung injury. Crit Care. 2010;14(3):R114.
37. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004;170(7):766-772.
38. Peres e Serra A, Parra ER, Eher E, Capelozzi VL. Nonhomogeneous Immunostaining of hyaline membranes in different manifestations of diffuse alveolar damage. Clinics (Sao Paulo). 2006;61(6):497-502.
39. Cowley HC, Heney D, Gearing AJ, Hemingway I, Webster NR. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Crit Care Med. 1994;22(4):651-657.
40. Kayal S, Jäis JP, Aguini N, Chaudière J, Labrousse J. Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med. 1998;157(3, pt1):776-784.
41. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Critical Care. 2008;12(2):R41.
42. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L514-521.
43. Sapru A, Calfee CS, Liu KD, et al; NHLBI ARDS Network. Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome [published correction appears in Intensive Care Med. 2015;41(3): 574]. Intensive Care Med. 2015;41(3):470-478.
44. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2007;35(8):1821-1828.
45. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003;285(1):L20-28.
46. Agrawal A, Zhuo H, Brady S, et al. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L634-639.
47. Cartin-Ceba R, Hubmayr RD, Qin R, et al. Predictive value of plasma biomarkers for mortality and organ failure development in patients with acute respiratory distress syndrome. J Crit Care. 2015;30(1):219 e1-e7.
48. Ware LB, Fremont RD, Bastarache JA, Calfee CS, Matthay MA. Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma protein ratio. Eur Respir J. 2010;35(2):331-337.
49. Bastarache JA, Wang L, Geiser T, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax. 2007;62(7):608-616.
50. Bastarache JA, Sebag SC, Clune JK, et al. Low levels of tissue factor lead to alveolar haemorrhage, potentiating murine acute lung injury and oxidative stress. Thorax. 2012;67(12):1032-1039.
51. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163(6):1376-1383.
52. Levayer R, Lecuit T. Breaking down EMT. Nat Cell Biol. 2008;10(7):757-759.
53. Tiozzo C, De Langhe S, Yu M, et al. Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury. Am J Respir Crit Care Med. 2009;180(8):701-712.
54. Miyoshi K, Yanagi S, Kawahara K, et al. Epithelial Pten controls acute lung injury and fibrosis by regulating alveolar epithelial cell integrity. Am J Respir Crit Care Med. 2013;187(3):262-275.
55. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax. 2008;63(12):1083-1089.
56. Matsuse T, Ohga E, Teramoto S, et al. Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. J Clin Pathol. 1998;51(7):515-519.
57. Nathani N, Perkins GD, Tunnicliffe W, et al. Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome. Crit Care. 2008;12(1):R12.
58. Ohtsuki Y, Fujita J, Hachisuka Y, et al. Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia. Med Mol Morphol. 2007;40(4):198-202.
59. Cheng IW, Ware LB, Greene KE, Nuckton TJ, Eisner MD, Matthay MA. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med. 2003;31(1):20-27.
60. Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009;135(6):1440-1447.
61. Newman V, Gonzalez RF, Matthay MA, Dobbs LG V. A novel alveolar type I cell-specific biochemical marker of human acute lung injury. Am J Respir Crit Care Med. 2000;161(3):990-995.
62. Albertine KH, Soulier MF, Wang Z, et al. Fas and fas ligand are upregulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol. 2002;161(5):1783-1796.
63. Cavalcante FS, Ito S, Brewer KK, et al. Mechanical interactions between collagen and proteoglycans: implications for the stability of lung tissue. J Appl Physiol. 2005;98:672-679.
64. Takahashi A, Majumdar A, Parameswaran H, Bartolák-Suki E, Suki B. Proteoglycans maintain lung stability in an elastase-treated mouse model of emphysema. Am J Respir Cell Mol Biol. 2014;51(1):26-33.
65. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment [published correction appears in Am J Respir Crit Care Med. 2013;188(12):1477]. Am J Respir Crit Care Med. 1998;158 (5, pt1) :1432-1441.
66. Synenki L, Chandel NS, Budinger GR, et al. Bronchoalveolar lavage fluid from patients with acute lung injury/acute respiratory distress syndrome induces myofibroblast differentiation. Crit Care Med. 2007;35(3):842-848.
67. Quesnel C, Piednoir P, Gelly J, et al. Alveolar fibrocyte percentage is an independent predictor of poor outcome in patients with acute lung injury. Crit Care Med. 2012;40(1):21-28.
68. Torii K, Iida K, Miyazaki Y, et al. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155(1):43-46.
69. McClintock DE1 Starcher B, Eisner MD, et al. Higher urine desmosine levels are associated with mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):L566-571.
70. Fligiel SE, Standiford T, Fligiel HM, et al. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol. 2006;37(4):422-430.
71. Ware LB, Koyama T, Billheimer DD, et al; NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010;137(2):288-296.
72. Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care. 2013;17(5):R253.